Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2004 Mar-Apr;19(2):81–88. doi: 10.1177/153331750401900215

Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study

Rita Moretti 1, Paola Torre, Rodolfo M Antonello, Tatiana Cattaruzza, Giuseppe Cazzato 2, Antonio Bava 3
PMCID: PMC10833965  PMID: 15106388

Abstract

Disabilities caused by behavioral problems can be potentially devastating in cognitively impaired patients. These behavioral symptoms can be a major cause of stress, anxiety, and concern for caregivers. While psychotropic drugs are frequently used to control these symptoms, they can be accompanied by significant side effects, which include sedation, disinhibition, depression, falls, incontinence, parkinsonism, and akathisias. Agitation is a major problem in older patients with dementia. Agitation and aggression have always been difficult behaviors to manage, and when it is severe, agitation can be a behavioral emergency that requires urgent and immediate intervention.

This six-month study included a group of 94 outpatients (48 men and 46 women) who had a diagnosis of subcortical vascular dementia (VaD). To be eligible for the study, patients needed a score of at least 3 for agitation/ aggression on the Neuropsychiatric Inventory (NPI), suggesting at least moderate frequency and/or severity, and 0 for delusions and hallucinations. Patients were divided into two homogenous groups. Group A received olanzapine (2.5-5 mg/day) and Group B received bromazepam (0.25 percent, 15 drops, three times per day). Patients in both groups were allowed to continue any previous therapy. Patients receiving olanzapine at an average dose of 3.21 ± 1.02 mg/day showed statistically significant improvement on the anxiety rating compared with those receiving bromazepam. Our patients had a host of medical conditions and received numerous concomitant medications. Given the potential complications associated with these therapeutic agents, these patients tolerated olanzapine quite well. It appeared that adverse events, particularly somnolence, postural instability, and postural hypotension, were mild and transient. Moreover, no anticholinerigic effect was registered. These findings suggest that olanzapine could be a safe and effective treatment for anxiety in cognitively impaired patients.

Keywords: agitation, behavior, vascular dementia, BEHAVE-AD, NPI

Full Text

The Full Text of this article is available as a PDF (113.1 KB).

Contributor Information

Rita Moretti, Dipartimento di Fisiologia e Patologia, Università di Trieste; Dipartimento di Medicina Clinica e Neurologia, UCO di Neurologia, Sezione Disturbi Cognitivi, Università di Trieste, Trieste, Italy..

Giuseppe Cazzato, Dipartimento di Medicina Clinica e Neurologia, UCO di Neurologia, Sezione Disturbi Cognitivi, Università di Trieste, Trieste, Italy..

Antonio Bava, Dipartimento di Fisiologia e Patologia, Università di Trieste, Trieste, Italy..

References

  1. Feifel D: Psychopharmacology in the Acute Setting: Review and Proposed Guidelines. Psychiatric Times [serial online]. 2001; 18(5). Available at: http://www.psychiatrictimes.com/p010537.html. Accessed January 5, 2004. [Google Scholar]
  2. Mega MS, Cummings JL, Fiorello T, et al.: The spectrum of behavioral changes in Alzheimer's disease. Neuorology. 1996; 46(1): 130-135. [DOI] [PubMed] [Google Scholar]
  3. O'Donnell BF, Drachman DA, Barnes HJ, et al.: Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992; 5(1): 45-52. [DOI] [PubMed] [Google Scholar]
  4. Kaufer D: Treatment of Behavioral Symptoms in Alzheimer's Disease. American Academy of Neurology. 2000; 5TP: 001-7-19-001-7-19. [Google Scholar]
  5. Mintzer JE, Brawman-Mintzer O, Mirski D, et al.: Anxiety in the Behavioral and Psychological Symptoms of Dementia (BPSD). Int Psychogeriatrics. 2000; 12(S1): 139-142. [Google Scholar]
  6. Stern RG, Duffelmeyer ME, Zemishlani Z, et al.: The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psyhiatr Clin North Am. 1991; 14(2): 375-384. [PubMed] [Google Scholar]
  7. Borson S, Raskind MA: Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology. 1997; 48(5 Suppl 6): S17-S24. [DOI] [PubMed] [Google Scholar]
  8. Small GW, Rabins PV, Barry PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA. 1997; 278(16): 1363-1371. [PubMed] [Google Scholar]
  9. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998; 155(11): 1512-1520. [DOI] [PubMed] [Google Scholar]
  10. De Deyn PP, Rabheru K, Rasmussen A, et al.: A randomized trial of risperidone, placebo, and haloperidol treatment for behavioral symptoms of dementia. Neurology. 1999; 53(5): 946-955. [DOI] [PubMed] [Google Scholar]
  11. Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999; 60(2): 107-115. [DOI] [PubMed] [Google Scholar]
  12. McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999; 60(5): 292-298. [PubMed] [Google Scholar]
  13. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebocontrolled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000; 57(10): 968-976. [DOI] [PubMed] [Google Scholar]
  14. Wood S, Cummings JL, Hsu MA, et al.: The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry.2000; 8(1): 75-83. [DOI] [PubMed] [Google Scholar]
  15. Román GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology. 1993; 43(2): 250-260. [DOI] [PubMed] [Google Scholar]
  16. Erkinjuntti T, Bowler JV, DeCarli CS, et al.: Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord.1999; 13(Suppl 3): S81-S90. [PubMed] [Google Scholar]
  17. Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140: 566-572. [DOI] [PubMed] [Google Scholar]
  18. Folstein M, Folstein S, McHugh P: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189-198. [DOI] [PubMed] [Google Scholar]
  19. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 44(12): 2308-2314. [DOI] [PubMed] [Google Scholar]
  20. Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987; 48(Suppl): 9-15. [PubMed] [Google Scholar]
  21. Conwell Y, Forbes NT, Cox C, et al.: Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc.1993; 41(1): 38-41. [DOI] [PubMed] [Google Scholar]
  22. Greene JG, Smith R, Gardiner M, et al.: Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing. 1982; 11(2): 121-126. [DOI] [PubMed] [Google Scholar]
  23. Teri L, Borson S, Kiyak HA, et al.: Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc.1990; 37(2): 109-116. [DOI] [PubMed] [Google Scholar]
  24. Teri L, Logsdon RG, Perskind E, et al.: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000; 55(9): 1271-1278. [DOI] [PubMed] [Google Scholar]
  25. Masterman D: Treatment of neuropsychiatric symptoms of Alzheimer's disease. American Academy of Neurology. 2001; 6TP: 001-19-33-001-19-33. [Google Scholar]
  26. Folstein MF, Bylsma FW: Noncognitive symptoms of Alzheimer Disease. In RD Terry RD, Katzmann R, Bick KL, et al. (eds.): Alzheimer Disease. 2nd Edition. Philadelphia: Lippincott Williams & Wilkins, 1999; 25-37. [Google Scholar]
  27. Schneider LS, Pollack VE, Lyness SA: A Metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990; 38(5): 553-563. [DOI] [PubMed] [Google Scholar]
  28. De Deyn PP, Katz IR: Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry. 2000; 15(Suppl 1): S14-S22. [DOI] [PubMed] [Google Scholar]
  29. Brodaty H, Ames D, Snowdon J: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry.2003; 64(2): 134-143. [DOI] [PubMed] [Google Scholar]
  30. Kennedy JS, Zagar A, Bymaster F, et al.: The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry.2001; 16(Suppl 1): S24-S32. [DOI] [PubMed] [Google Scholar]
  31. Moretti R, Torre P, Antonello RM, et al.: Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen.2003; 18(4): 205-214. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES